Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

289 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome.
Koo RM, Wong E, Davis JE, Perera T, Lim A, Koldej RM, Ritchie DS. Koo RM, et al. Among authors: perera t. Bone Marrow Transplant. 2024 Jul;59(7):1025-1027. doi: 10.1038/s41409-023-02195-x. Epub 2024 Mar 27. Bone Marrow Transplant. 2024. PMID: 38538726 Clinical Trial. No abstract available.
The improvement in overall survival from unrelated donor transplantation in Australia and New Zealand is driven by a reduction in non-relapse mortality: A study from the ABMTRR.
Kliman D, Tran S, Kennedy G, Curley C, McLean A, Gottlieb D, Kwan J, Ritchie D, Chee L, Spencer A, Purtill D, Bardy P, Larsen S, Chien N, Perera T, Greenwood M, Hamad N, Moore J. Kliman D, et al. Among authors: perera t. Bone Marrow Transplant. 2022 Jun;57(6):982-989. doi: 10.1038/s41409-022-01683-w. Epub 2022 Apr 19. Bone Marrow Transplant. 2022. PMID: 35440804
Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry.
Lwin Y, Kennedy G, Gottlieb D, Kwan J, Ritchie D, Szer J, Milliken S, Browett P, Spencer A, Butler A, Bardy P, Greenwood M, Perera T, He S, McEwan A, Larsen S, Lai H, Purtill D, Tran S, Aarons D, Hamad N. Lwin Y, et al. Among authors: perera t. Biol Blood Marrow Transplant. 2020 Dec;26(12):2252-2261. doi: 10.1016/j.bbmt.2020.08.024. Epub 2020 Aug 27. Biol Blood Marrow Transplant. 2020. PMID: 32861814 Free article.
Bone Marrow Transplant Society of Australia and New Zealand COVID-19 consensus position statement.
Hamad N, Gottlieb D, Ritchie D, Kennedy G, Watson AM, Greenwood M, Doocey R, Perera T, Spencer A, Wong E, O'Brien T, Shaw P, Conyers R, Cole T, Milliken S, Bardy P, Larsen S, Lai H, Butler A, Fraser C, Bajel A, Butler J, Kerridge I, Purtill D. Hamad N, et al. Among authors: perera t. Intern Med J. 2020 Jun;50(6):774-775. doi: 10.1111/imj.14867. Intern Med J. 2020. PMID: 32537929 Free PMC article. No abstract available.
Australia and New Zealand Transplant and Cellular Therapies COVID-19 vaccination consensus position statement.
Hamad N, Ananda-Rajah M, Gilroy N, MacIntyre R, Gottlieb D, Ritchie D, Harrison S, Kennedy G, Watson AM, Greenwood M, Doocey R, Perera T, Spencer A, Wong E, O'Brien T, Shaw P, Conyers R, Milliken S, Bardy P, Larsen S, Ho PJ, Lai H, Bajel A, Butler J, Tiley C, D'Rozario J, Johnston A, Cochrane T, Mills T, Irving I, Pullon H, Purtill D. Hamad N, et al. Among authors: perera t. Intern Med J. 2021 Aug;51(8):1321-1323. doi: 10.1111/imj.15263. Intern Med J. 2021. PMID: 34423546 Free PMC article.
Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P, Dasyam N, Giunti G, Mester B, Bauer E, Andrews B, Perera T, Ostapowicz T, Frampton C, Li P, Ritchie D, Bollard CM, Hermans IF, Weinkove R. George P, et al. Among authors: perera t. BMJ Open. 2020 Feb 9;10(2):e034629. doi: 10.1136/bmjopen-2019-034629. BMJ Open. 2020. PMID: 32041862 Free PMC article.
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators. Levis MJ, et al. J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12. J Clin Oncol. 2024. PMID: 38471061 Free PMC article. Clinical Trial.
Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma.
Thompson PA, Perera T, Marin D, Oran B, Popat U, Qazilbash M, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Anderlini P, Rondon G, Alousi A, Ciurea S, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie D, Hosing CM. Thompson PA, et al. Among authors: perera t. Leuk Lymphoma. 2016 Jul;57(7):1607-15. doi: 10.3109/10428194.2015.1105370. Epub 2015 Dec 23. Leuk Lymphoma. 2016. PMID: 26472485 Free PMC article.
289 results